Takeda's Vedolizumab SC Receives CHMP's Positive Opinion as a Maintenance Therapy for Moderately to Severely Active UC or CD
Shots:
- The CHMP’s positive opinion is based on P-III VISIBLE study assessing vedolizumab (SC) as maintenance therapy vs PBO in ~1000 patients with moderately to severely active UC & CD who achieved clinical response @6wks. following the 2doses of vedolizumab (IV) @0 & 2wks.
- EC will now review the CHMP’s positive opinion and if approved- vedolizumab will be the only maintenance therapy for UC & CD with both IV & SC formulation in the EU
- Vedolizumab SC is a gut-selective biologic act by inhibiting alpha4beta7 integrin binding to MAdCAM-1 and not VCAM-1 and is expected to be available in both pre-filled syringe and a pre-filled pen
Click here to read full press release/ article
Ref: Takeda | Image: Takeda
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com